Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.

Intest Res · 2020 · PMC7609395 · PMID 32646198

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A Cochrane systematic review with 53 RCTs of parallel design, with minimum treatment duration of 4 weeks (n = 8,548) concluded that the difference in incidence of adverse events with 5-ASA agents and placebo did not reach statistical significance.

also in 111,027 other papers

marginally nonsignificantno p-value reported

In another systematic review 5-ASA use was found to be protective for CRC (RR, 0.70; 95% CI, 0.51–0.94) and the effect was dose-dependent; the effect with sulfasalazine was marginally nonsignificant (RR, 0.72; 95% CI, 0.51–1.01) [ 157 ].

also in 448 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.